|
⚲
|
| Keyboard |
| Campbell Shannon
✚
|
|
|---|---|
| CIK # | 0002018966 |
| EDGAR Form | CIK | 2011 - 2026 |
|---|---|---|
| 3 | [0002018966] | |
| 4 | [0002018966] |
| Form 3/4/5 Subject | 2011 - 2026 |
|---|---|
| Campbell Shannon | |
| Black Diamond Therapeutics Inc | |
| Zentalis Pharmaceuticals Inc |
| Insider Transaction (Form 3/4/5) | Date | Action | Shares | Price | Value ($) |
|---|---|---|---|---|---|
|
Black Diamond Therapeutics Inc BDTX
Stock Option (Right to Buy) · derivative
|
2025-06-12 | Grant | 30,550 | $0.00 | |
|
Black Diamond Therapeutics Inc BDTX
Common Stock
|
2024-12-13 | Grant | 4,500 | $2.50 | 11,250 |
|
Black Diamond Therapeutics Inc BDTX
Common Stock
|
2024-09-20 | Grant | 2,354 | $4.78 | 11,252 |
|
Black Diamond Therapeutics Inc BDTX
Common Stock
|
2024-06-21 | Grant | 2,011 | $4.98 | 10,015 |
|
Black Diamond Therapeutics Inc BDTX
Stock Option (Right to Buy) · derivative
|
2024-06-06 | Grant | 30,550 | $0.00 | |
|
Black Diamond Therapeutics Inc BDTX
Stock Option (Right to Buy) · derivative
|
2024-04-10 | Grant | 61,100 | $0.00 |